RNA interference therapy targeting hepatic angiotensinogen for the treatment of hypertension and cardiovascular disease: a first-in-human and proof-of-concept study

QCZ484 - Novartis

https://digital-congress.escardio.org/ESC-Congress/Sessions/19798

Y He1; L Filosa 1; G van Wyk 2; M Samanta2; C Watters1; FB Saches1; E Nimz1; Y Li3; J jin3; I Leelasena4; P Hamilton5; R Friend6; M De Sciscio 7; CJ O'Donnell1

May 11, 2026